HRP20080648A2 - Fuzijski peptid za inhibiranje interakcija izmeđuneuronskog receptora nmda (nmdar) te proteina koji reagiraju s nmdar - Google Patents

Fuzijski peptid za inhibiranje interakcija izmeđuneuronskog receptora nmda (nmdar) te proteina koji reagiraju s nmdar

Info

Publication number
HRP20080648A2
HRP20080648A2 HR20080648A HRP20080648A HRP20080648A2 HR P20080648 A2 HRP20080648 A2 HR P20080648A2 HR 20080648 A HR20080648 A HR 20080648A HR P20080648 A HRP20080648 A HR P20080648A HR P20080648 A2 HRP20080648 A2 HR P20080648A2
Authority
HR
Croatia
Prior art keywords
nmdar
fusion peptide
interacting proteins
component
inhibiting interaction
Prior art date
Application number
HR20080648A
Other languages
English (en)
Inventor
Meyer Thomas
Original Assignee
Xigen S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xigen S.A. filed Critical Xigen S.A.
Publication of HRP20080648A2 publication Critical patent/HRP20080648A2/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

Ovaj izum osigurava fuzijski peptid koji obuhvaćanajmanje komponentu (I), pri čemu komponenta (I) obuhvaća peptid transporter te komponentu (II) izabranu između peptida koji inhibiraju interakcije neuronskih receptora N-metil-D-aspartat (NMDAR) s proteinima koji reagiraju s NMDAR, pri čemu se komponenta (II) u potpunosti sastoji od D-enantiomernih amino kiselina. Ovaj izum nadalje osigurava inventivnu farmaceutsku sastavinu, koja obuhvaća inventivni fuzijski peptid te postupke za primjenu istekao i komplete kemikalija te uporabe koje uključuju inventivni fuzijski peptid.
HR20080648A 2006-07-31 2008-12-12 Fuzijski peptid za inhibiranje interakcija izmeđuneuronskog receptora nmda (nmdar) te proteina koji reagiraju s nmdar HRP20080648A2 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06015911A EP1884521A1 (en) 2006-07-31 2006-07-31 Fusion peptide for inhibiting interaction of neuronal NMDA receptor (NMDAR) and NMDAR interacting proteins
PCT/EP2007/006619 WO2008014917A1 (en) 2006-07-31 2007-07-25 Fusion peptide for inhibiting interaction of neuronal nmda receptor (nmdar) and nmdar interacting proteins

Publications (1)

Publication Number Publication Date
HRP20080648A2 true HRP20080648A2 (hr) 2009-02-28

Family

ID=37084687

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20080648A HRP20080648A2 (hr) 2006-07-31 2008-12-12 Fuzijski peptid za inhibiranje interakcija izmeđuneuronskog receptora nmda (nmdar) te proteina koji reagiraju s nmdar

Country Status (15)

Country Link
US (1) US20090281036A1 (hr)
EP (2) EP1884521A1 (hr)
JP (1) JP2009545543A (hr)
KR (1) KR20090033868A (hr)
CN (1) CN101490081A (hr)
AT (1) ATE509948T1 (hr)
AU (1) AU2007280717A1 (hr)
BR (1) BRPI0714783A2 (hr)
CA (1) CA2653438A1 (hr)
HR (1) HRP20080648A2 (hr)
IL (1) IL195536A0 (hr)
MX (1) MX2009001095A (hr)
NO (1) NO20090875L (hr)
RU (1) RU2009106710A (hr)
WO (1) WO2008014917A1 (hr)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8685925B2 (en) 2006-07-11 2014-04-01 Nono Inc. Method and compositions for treating stroke with fever
GB0804496D0 (en) * 2008-03-11 2008-04-16 Theryte Ltd Treating cancer
DK2307035T3 (da) * 2008-05-16 2014-01-20 Nono Inc Anvendelse af en PSD-95 inhibitor ved behandlingen af epilepsi
JP5801197B2 (ja) 2008-09-03 2015-10-28 ノノ インコーポレイテッド 痛みの治療に関する薬剤及び方法
HUE046640T2 (hu) 2009-06-10 2020-03-30 Nono Inc TAT-internalizáló peptidhez kapcsolt hatóanyag együttes beadása egy hízósejt degranuláció-inhibitorral
HUE053131T2 (hu) * 2009-06-10 2021-06-28 Nono Inc Kezelési rendszer neurológiai betegség kezelésére
WO2012021854A2 (en) * 2010-08-12 2012-02-16 Nono, Inc. Treatment of penetrative injury to the brain
JP5857056B2 (ja) 2010-10-14 2016-02-10 ザイジェン インフラメーション エルティーディー 慢性又は非慢性の炎症性眼疾患を治療するためのｊｎｋシグナル伝達経路の細胞透過性ペプチド阻害剤の使用
WO2012158624A2 (en) 2011-05-13 2012-11-22 The Board Of Trustees Of The Leland Stanford Junior University Inhibitors of mitochondrial fission and methods of use thereof
PT3427748T (pt) 2011-06-24 2022-05-03 Nono Inc Terapia de combinação para isquemia
WO2013054110A2 (en) * 2011-10-10 2013-04-18 University Of Lancaster Compositions for binding to amyloid proteins
US9241970B2 (en) 2011-12-13 2016-01-26 Nono Inc. Therapy for subarachnoid hemorrhage and ischemia
SG11201403239UA (en) * 2011-12-13 2014-09-26 Nono Inc Therapy for subarachnoid hemorrhage and ischemia
WO2013091670A1 (en) 2011-12-21 2013-06-27 Xigen S.A. Novel jnk inhibitor molecules for treatment of various diseases
ES2725598T3 (es) * 2012-11-28 2019-09-25 Nono Inc Formulación liofilizada de Tat-NR2B9C
US10251935B2 (en) 2012-11-28 2019-04-09 Nono Inc. Lyophilized formulation comprising tat-NR2B9C, histidine and trehalose
US20140296164A1 (en) * 2013-03-29 2014-10-02 Calista Therapeutics, Inc. Compositions and methods of use for cell targeted inhibitors of the Cystic Fibrosis transmembrane regulator associated ligand
WO2014206427A1 (en) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
JP2016523274A (ja) 2013-06-26 2016-08-08 ザイジェン インフラメーション リミテッド 種々の疾患を処置するためのｊｎｋシグナル伝達経路の新規の細胞透過性ペプチド阻害剤の使用
WO2015197097A1 (en) 2014-06-26 2015-12-30 Xigen Inflammation Ltd. New use for jnk inhibitor molecules for treatment of various diseases
EP3063168B1 (en) 2013-10-30 2019-03-06 University of Western Australia Neuroprotective peptides
CN103804500B (zh) * 2014-01-22 2015-12-30 广州军区广州总医院 用于治疗慢性疼痛的多肽
US10287334B2 (en) * 2014-03-07 2019-05-14 The Arizona Board Of Regents On Behalf Of The University Of Arizona Non-narcotic CRMP2 peptides targeting sodium channels for chronic pain
CN103936838B (zh) * 2014-04-10 2015-10-28 武汉启瑞科技发展有限公司 小分子多肽TAT-p53DM及其在制备治疗或预防缺血性卒中药物中的应用
CN114057895A (zh) 2014-05-28 2022-02-18 诺诺公司 TAT-NR2B9c的氯盐
WO2015181757A1 (en) * 2014-05-28 2015-12-03 Nono Inc. Lyophilized formulation of tat-nr2b9c with acetylation scavenger
EP3190129B1 (en) * 2014-09-02 2020-01-08 Tokyo University of Science Foundation Centrally-acting peptide derivative, and pharmaceutical composition
CN104650242A (zh) * 2015-01-13 2015-05-27 河南科技大学 一种融合多肽及其制备方法和应用
US10688153B2 (en) 2015-11-06 2020-06-23 The Board Of Trustees Of The University Of Illinois Peptides and method for treatment of cardiac arrest
ES2869300T3 (es) * 2016-04-27 2021-10-25 Biocells Beijing Biotech Co Ltd Péptido terapéutico para las lesiones relacionadas con la neurotoxicidad excitadora
US11208446B2 (en) * 2016-11-01 2021-12-28 Memorial Sloan Kettering Cancer Cenier Agents and methods for treating CBP-dependent cancers
WO2018103038A1 (zh) * 2016-12-08 2018-06-14 拜西欧斯（北京）生物技术有限公司 一种缀合物及其应用
EP3784261A4 (en) * 2017-04-02 2021-11-03 InterK Peptide Therapeutics Limited COMPOSITIONS AND METHODS FOR THE PREVENTION OR TREATMENT OF PAIN
WO2019006692A1 (zh) * 2017-07-05 2019-01-10 拜西欧斯（北京）生物技术有限公司 用于治疗、改善或预防神经系统相关病症的化合物及其用途
EA039314B1 (ru) 2017-07-05 2022-01-12 Биоселз (Бейдзин) Биотек Ко., Лтд. Фармацевтически приемлемые соли полипептидов и их применение
JP2022549057A (ja) 2019-07-11 2022-11-24 厦▲門▼大学 分子の細胞内送達のための複合体
JP2023509666A (ja) 2019-12-31 2023-03-09 シァメン・ユニヴァーシティ 分子の細胞内送達用の多量体化送達システム
US20230055441A1 (en) * 2020-01-09 2023-02-23 Nono Inc. Plasmin-resistant peptides for treating stroke and related conditions
CN114539358B (zh) * 2020-11-19 2023-09-15 中国科学院大连化学物理研究所 一种多肽及制备方法与应用
CN112853559B (zh) * 2020-12-31 2021-10-08 盐城师范学院 一种基于环锭纺纱线质量的工序约束嵌套控制系统及方法
CN113735938A (zh) * 2021-07-30 2021-12-03 英纳氏(珠海)药业有限公司 一种神经保护多肽化合物及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7410998A (en) * 1996-11-26 1998-06-22 Johns Hopkins University, The Ligand detection system and methods of use thereof
US7510824B2 (en) * 1999-06-02 2009-03-31 Nono Inc. Method of screening peptides useful in treating traumatic injury to the brain or spinal cord
EP1578365A4 (en) * 2002-11-14 2009-09-23 Arbor Vita Corp MOLECULAR INTERACTIONS IN NEURONS

Also Published As

Publication number Publication date
MX2009001095A (es) 2009-02-10
JP2009545543A (ja) 2009-12-24
CA2653438A1 (en) 2008-02-07
RU2009106710A (ru) 2010-09-10
BRPI0714783A2 (pt) 2013-07-30
EP1884521A1 (en) 2008-02-06
WO2008014917A1 (en) 2008-02-07
CN101490081A (zh) 2009-07-22
IL195536A0 (en) 2011-08-01
US20090281036A1 (en) 2009-11-12
EP2046821B1 (en) 2011-05-18
AU2007280717A1 (en) 2008-02-07
KR20090033868A (ko) 2009-04-06
EP2046821A1 (en) 2009-04-15
ATE509948T1 (de) 2011-06-15
NO20090875L (no) 2009-02-25

Similar Documents

Publication Publication Date Title
IL195536A0 (en) Fusion peptide for inhibiting interaction of neuronal nmda receptor (nmdar) and nmdar interacting proteins
ATE491349T1 (de) Neue nutrazeutika-zusammensetzungen
BRPI0809366B8 (pt) polipeptídeo substancialmente alfa-helicoidal, método para fabricação do mesmo, aminoácido e composição farmacêutica
WO2006097536A3 (en) Dimeric peptide agonists of the glp-1 receptor
IL195338A (en) An antibody comprising an FC variant containing amino acid replaces d or e at position 239, a medicament containing it and its use
RS50966B (sr) Agonisti pyy i njihova upotreba
WO2008079995A3 (en) Conjugate of natriuretic peptide and antibody constant region
MX2009006199A (es) Formulacion parenteral de anticuerpos abeta.
JOP20190083A1 (ar) بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
EP2617431A3 (en) Polypeptide inhibitors of HSP27 kinase and uses therefor
EA200802128A1 (ru) Новые нутрицевтические композиции
SI1848458T1 (sl) Uporaba aktiviranega polimera za ločevanje proteina in polipeptidnih multimerov
AU2002217010A1 (en) Peptides, the production and use thereof for binding immunoglobulins
AP2004003144A0 (en) Amino acids with affinity for the a2d-protein
WO2006042745A3 (de) Chemisch modifizierte iapp - peptidanaloga
WO2005074626A3 (en) Compositions, methods and uses for a novel family of peptides
WO2008093058A3 (en) Peptides and their use
IL223076A0 (en) Novel as160-like protein, test systems, methods and uses involving it for the identification of diabetes type 2 therapeutics
IL173764A0 (en) Amino acids with affinity for the alpha2delta-protein
WO2006094014A3 (en) Methods for diagnosis and treatment of endometrial cancer
BRPI0516922A (pt) composto de ribavirina, método para fazer um composto de ribavirina, método para usar um composto de ribavirina e composição farmacêutica
WO2005059131A3 (en) Protein binding miniature proteins and uses thereof
WO2007047962A3 (en) Insecticides that target protein kinase a (pka)
WO2008081812A1 (ja) 抗腫瘍ペプチド及びその利用
WO2008100290A3 (en) Recombinant rhinovirus vectors

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
ODRP Renewal fee for the maintenance of a patent

Payment date: 20100721

Year of fee payment: 4

OBST Application withdrawn